Literature DB >> 30523419

β-Cyclodextrin-based inclusion complexes and nanocomposites of rivaroxaban for solubility enhancement.

Atul P Sherje1, Mrunal Jadhav2.   

Abstract

Rivaroxaban (RIV) is an oral anticoagulant used in the prevention of venous thromboembolism in adult patients after total hip replacement or total knee replacement surgery. It is practically insoluble in water and buffer systems (pH 3-9). The present study was aimed to investigate the β-CD-based inclusion complexes and nanocomposites of rivaroxaban (RIV) for solubility and dissolution enhancement. A novel solubility enhancement approach of inclusion complexation of RIV with β-CD using spray drying method combined with high pressure homogenization as a particle engineering method was used. Change in crystallinity of RIV nanocomposites was assessed by DSC and PXRD. The interaction of drug with β-CD was projected through 1H-NMR and FT-IR studies. Saturation solubility and in vitro dissolution study revealed a dramatic increase in solubility and dissolution of RIV, respectively. Thus, spray-dried β-CD-based nanocomposites could be an innovative approach for solubility and dissolution enhancement of RIV.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30523419     DOI: 10.1007/s10856-018-6194-6

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  18 in total

1.  Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound.

Authors:  Edit Baka; John E A Comer; Krisztina Takács-Novák
Journal:  J Pharm Biomed Anal       Date:  2007-11-01       Impact factor: 3.935

2.  Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone.

Authors:  Seulki Lee; Sang Kyoon Kim; Dong Yun Lee; Kyeongsoon Park; Tadiparthi Suresh Kumar; Su Young Chae; Youngro Byun
Journal:  J Pharm Sci       Date:  2005-11       Impact factor: 3.534

3.  Alpinetin/hydroxypropyl-β-cyclodextrin host-guest system: preparation, characterization, inclusion mode, solubilization and stability.

Authors:  Shui-Xian Ma; Wen Chen; Xiao-Dong Yang; Na Zhang; Shao-Jie Wang; Lin Liu; Li-Juan Yang
Journal:  J Pharm Biomed Anal       Date:  2012-05-03       Impact factor: 3.935

4.  Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity.

Authors:  Shankar Swaminathan; Linda Pastero; Loredana Serpe; Francesco Trotta; Pradeep Vavia; Dino Aquilano; Michele Trotta; Gianpaolo Zara; Roberta Cavalli
Journal:  Eur J Pharm Biopharm       Date:  2009-11-10       Impact factor: 5.571

5.  Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether beta-cyclodextrin binary and ternary complexes.

Authors:  Laura Ribeiro; Thorsteinn Loftsson; Domingos Ferreira; Francisco Veiga
Journal:  Chem Pharm Bull (Tokyo)       Date:  2003-08       Impact factor: 1.645

Review 6.  Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Authors:  Sean T Duggan; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

7.  Comparative interaction of 2-hydroxypropyl-beta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions.

Authors:  Marcus E Brewster; Roger Vandecruys; Jef Peeters; Peter Neeskens; Geert Verreck; Thorsteinn Loftsson
Journal:  Eur J Pharm Sci       Date:  2008-02-26       Impact factor: 4.384

8.  CDs as solubilizers: effects of excipients and competing drugs.

Authors:  Phatsawee Jansook; Thorsteinn Loftsson
Journal:  Int J Pharm       Date:  2009-06-12       Impact factor: 5.875

9.  Synthesis, characterization and in vitro release studies of a new acetazolamide-HP-beta-CD-TEA inclusion complex.

Authors:  Gladys E Granero; Marcos M Maitre; Claudia Garnero; Marcela R Longhi
Journal:  Eur J Med Chem       Date:  2007-04-24       Impact factor: 6.514

Review 10.  Cyclodextrins as pharmaceutical solubilizers.

Authors:  Marcus E Brewster; Thorsteinn Loftsson
Journal:  Adv Drug Deliv Rev       Date:  2007-05-29       Impact factor: 15.470

View more
  3 in total

1.  Amalgamation of solid dispersion and melt adsorption techniques for augmentation of oral bioavailability of novel anticoagulant rivaroxaban.

Authors:  Pranav J Shah; Milan P Patel; Jigar Shah; Anroop B Nair; Sabna Kotta; Bhavin Vyas
Journal:  Drug Deliv Transl Res       Date:  2022-04-25       Impact factor: 4.617

2.  Sustained release and enhanced oral bioavailability of rivaroxaban by PLGA nanoparticles with no food effect.

Authors:  Md Khalid Anwer; Muqtader Mohammad; Muzaffar Iqbal; Mohd Nazam Ansari; Essam Ezzeldin; Farhat Fatima; Saad M Alshahrani; Mohammed F Aldawsari; Ahmed Alalaiwe; Aiman A Alzahrani; Abdullah M Aldayel
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

3.  Solubilized ubiquinol for preserving corneal function.

Authors:  Youssef W Naguib; Sanjib Saha; Jessica M Skeie; Timothy Acri; Kareem Ebeid; Somaya Abdel-Rahman; Sandeep Kesh; Gregory A Schmidt; Darryl Y Nishimura; Jeffrey A Banas; Min Zhu; Mark A Greiner; Aliasger K Salem
Journal:  Biomaterials       Date:  2021-05-01       Impact factor: 15.304

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.